Disclaimer: This article is for educational and informational purposes only and does not constitute legal advice. Laws regarding Amanita muscaria and its constituents vary by jurisdiction and are subject to change. Consult a qualified attorney in your jurisdiction for guidance on your specific situation.
By HealthDataConsortium.org Policy & Consumer Research Team | March 21, 2026
You've seen Amanita muscaria gummies sold openly online, at smoke shops, and even at gas stations. They contain a psychoactive compound that alters consciousness. So the obvious question is: how is this legal?
The answer is surprisingly simple at the federal level but gets more complicated when you factor in the FDA's recent position, state-specific laws, and the evolving regulatory environment. Here's the complete picture as of March 2026.
Federal Legal Status: Not a Controlled Substance
Amanita muscaria — including its primary psychoactive compound muscimol and its precursor ibotenic acid — is not listed on any schedule of the federal Controlled Substances Act (CSA). It never has been. This means that under federal law, Amanita muscaria and muscimol can be legally cultivated, purchased, possessed, and sold without a license or prescription.
This stands in sharp contrast to psilocybin mushrooms, which are classified as Schedule I controlled substances under the CSA — the same category as heroin and LSD. The distinction exists because muscimol and psilocybin are chemically unrelated compounds that work through different brain receptor systems. Federal drug scheduling is based on specific chemical compounds, not on whether a substance is “a mushroom” or “psychoactive.” If you're unclear on the differences between these two mushroom types, our comparison of Amanita muscaria vs. psilocybin explains the science.
The practical result: in 49 out of 50 states, you can legally buy, possess, and consume Amanita muscaria products. The one exception is Louisiana.
The Louisiana Exception
Louisiana is currently the only state that has explicitly banned Amanita muscaria. Under Louisiana Act No. 159, signed into law on June 28, 2005 and effective August 8, 2005, Amanita muscaria is listed among 40 plants that are illegal when intended for human consumption. The law prohibits the purchase, sale, and possession of Amanita muscaria products within the state.
Notably, the Louisiana law includes an exception for “possession, planting, cultivation, growing, or harvesting” of these plants when used “strictly for aesthetic, landscaping, or decorative purposes.” This means the mushroom itself is not banned — only its use as an ingestible product.
If you live in Louisiana or are shipping products to Louisiana addresses, Amanita muscaria products are not legal for human consumption in your state.
Every Other State: Currently Legal
As of March 2026, Amanita muscaria is fully legal in all 49 remaining states plus Washington D.C. There are no restrictions on product type, potency, purchase quantity, or possession amount. Products can be purchased in person at retail locations or ordered online for delivery.
However, this situation could change. Several factors make future state-level restrictions plausible: the growing commercial market for Amanita products is attracting regulatory attention, the FDA's December 2024 determination (discussed below) could prompt state food safety agencies to act, and if adverse event reports increase, states may follow Louisiana's approach. Consumers should stay informed about their state's current laws, as the regulatory environment for novel psychoactive products is historically dynamic.
The FDA's December 2024 Determination: What It Means and What It Doesn't
In December 2024, the U.S. Food and Drug Administration issued a significant determination regarding Amanita muscaria. After reviewing available information about the mushroom, its extracts, and its constituents (muscimol, ibotenic acid, and muscarine), the FDA concluded that:
Amanita muscaria and its constituents do not meet the safety standard for use in food.
They are not Generally Recognized as Safe (GRAS).
Their use as food ingredients may be harmful.
They constitute unapproved food additives.
The FDA noted that Amanita muscaria products have been marketed as “psychedelic edibles,” “legal psychedelics,” and “mushroom edibles” — framing that the agency views as promoting the mushroom's psychoactive properties in a food context.
What this determination means: The FDA has formally stated its position that Amanita muscaria should not be used as a food ingredient. This gives the agency a legal basis to take enforcement action against companies that market Amanita products as food items, particularly those using “Supplement Facts” panels or making food-type marketing claims. Companies that have not submitted safety data or filed applications required for food additives are technically selling products that do not comply with FDA food regulations.
What this determination does NOT mean: The FDA determination did not make Amanita muscaria illegal. It did not place muscimol on any controlled substance schedule. It did not ban the sale of Amanita products. It specifically addressed the food-ingredient classification — not the legality of the substance itself. The supplement and consumer product market continues to operate.
The distinction matters because the FDA's enforcement capacity is finite. The agency issues warning letters and takes enforcement action selectively, typically focusing on companies making specific health claims or those involved in adverse events. Whether and how aggressively the FDA will enforce this determination against the broader Amanita product market remains to be seen.
For consumers, the key takeaway is that the FDA has formally expressed safety concerns about these products. This doesn't mean you can't buy them, but it does mean the federal government's food safety authority has placed them in a category of products it considers potentially harmful.
How Amanita Muscaria Compares to Other Legal Psychoactive Substances
Understanding where Amanita muscaria falls in the broader legal picture helps clarify its unusual position:
Psilocybin mushrooms: Schedule I controlled substance federally. Decriminalized in some cities and states (Oregon, Colorado have established regulated access frameworks). Illegal to sell commercially in any state outside of licensed therapeutic settings.
Cannabis/THC: Schedule I federally (rescheduling to Schedule III pending as of 2026). Legal for medical use in 40 states, recreational use in 24 states. Still subject to federal enforcement in non-legal states and for federally regulated positions.
Kratom: Not federally scheduled. Banned in several states (Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin). FDA has issued import alerts and warnings but has not achieved a federal ban.
Amanita muscaria: Not federally scheduled. Banned in one state (Louisiana). FDA has issued a food-ingredient determination but not a product ban. No state has proposed additional restrictions as of March 2026.
Amanita muscaria currently occupies one of the least restricted positions among psychoactive substances in the United States. Whether this reflects a considered policy judgment or simply regulatory lag is debatable — but the practical reality for consumers is clear access in 49 states.
Drug Testing and Employment Considerations
Standard workplace drug panels — including the common 5-panel, 10-panel, and extended panel tests — do not screen for muscimol. These tests are designed to detect THC, opioids, cocaine, amphetamines, PCP, and in extended panels, substances like benzodiazepines, barbiturates, and alcohol metabolites. Muscimol is not among the target analytes for any standard employment screening.
This means that Amanita muscaria use will not produce a positive result on a standard employment drug test. Specialized forensic or clinical testing could theoretically identify muscimol if specifically requested, but this would be exceptional and is not part of routine screening.
However, consumers should be aware that some Amanita muscaria gummy products on the market are blended with other substances — including THC derivatives (Delta-8, Delta-9), kratom, or other compounds that could trigger positive drug test results. Always verify the complete ingredient list of any product and understand that a product marketed as “Amanita muscaria” may contain additional compounds. For guidance on evaluating product ingredients and quality, our 2026 product rankings break down exactly what each major brand contains.
International Legal Status
For readers outside the United States or those traveling internationally, the global legal status of Amanita muscaria varies:
Countries where Amanita muscaria is explicitly banned or controlled: Australia (muscimol is Schedule 9), the Netherlands (banned since December 2008), Romania (banned since February 2010), and Thailand (classified with hallucinogenic mushrooms).
Countries where it is legal or unregulated: Canada, the United Kingdom, Ireland, Mexico, Japan (sold openly in smart shops despite 2002 psilocybin scheduling), Sweden, and most of Europe (with country-specific variations).
Countries with unclear or disputed status: Russia has classified muscimol as a psychotropic substance, creating a complex legal situation given the mushroom's deep cultural roots in Russian and Siberian indigenous traditions.
This list is not exhaustive and legal status can change. Travelers should research the specific laws of their destination before carrying or purchasing Amanita muscaria products internationally.
What to Watch Going Forward
The Amanita muscaria market is growing rapidly — Google searches for the mushroom rose nearly 200% between 2022 and 2023 according to UC San Diego researchers, and the commercial product market has expanded significantly since then. Several developments could shift the legal environment:
FDA enforcement actions: The December 2024 determination gives the FDA a basis for action. Warning letters to specific manufacturers, import restrictions, or requirements for safety data submissions could materially affect the market.
State-level legislation: If adverse event reports increase or if the market continues to grow, additional states may follow Louisiana's approach. States with active supplement or food safety regulatory frameworks are the most likely candidates.
Industry self-regulation: Some manufacturers have begun adopting voluntary quality standards — including third-party testing, age restrictions, and childproof packaging — that mirror cannabis industry practices. Whether the industry self-regulates faster than government regulation arrives will significantly affect the consumer experience.
Potential federal scheduling: UC San Diego researchers have recommended placing Amanita muscaria on the Controlled Substances list for evaluation. While this has not gained legislative traction as of March 2026, it remains a possibility if safety concerns escalate.
For consumers, the practical advice is the same regardless of legal status: understand what you're consuming, verify product quality through third-party testing documentation, start with the lowest effective dose, and stay informed about regulatory developments in your jurisdiction. For detailed product evaluations and safety analysis, see our 2026 Amanita muscaria gummy rankings. For a deeper understanding of what these products actually contain and how they work, our guide on the science of Amanita muscaria covers the pharmacology in detail.
This article is part of HealthDataConsortium.org's consumer health research series examining emerging psychoactive substances, regulatory policy, and evidence-based product analysis.
